Fig. 1

PBMCs adhesion and transmigration. a PX induced a dose-dependent increase in PBMCs adhesion to BLECs monolayers. N = 10-14 wells per treatment, from three independent experiments. b-c Protein expression level of ICAM-1 and E-selectin was assessed after 24 h treatment with PX, using in cell western blot assay. For ICAM-1: N = 11-14 wells per treatment, from three independent experiments. E-selectin: N = 6 from a single experiment. d-f mRNA levels of the adhesion molecules were determined after 24 h treatment with PX, using RT-PCR. (N = 3 biological repeats with 3 technical repeats). g BLECs were treated with increasing concentrations of PX (24 h). Freshly isolated human PBMCs were fluorescently labeled and added to the luminal side and let to transmigrate for 4 h. N = 12 wells per treatment, from three independent experiments. h ICAM-1/CD54 neutralizing antibody (10 μg/ml) was added simultaneously with PX (600 μM, 24 h) to the transmigration assay. For LFA-1 inhibition, PBMCs were pre-incubated with LFA-1 antagonist (5 μM, for 45 min prior to addition of PBMCs). N = 8-10 wells per treatment, from two independent experiments. Data presented as means normalized to control ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. control, #p < 0.05 and ###p < 0.001 vs. PX